Polo样蛋白激酶1与乳腺癌发生、发展及治疗的相关性

Relationship of Polo-like kinase 1 to pathopoiesis,progress and therapy of breast cancer

乳腺癌是女性最常见的恶性肿瘤之一,发病率高,极易复发和转移,且具有年轻化趋势,靶向治疗已成为乳腺癌治疗的趋势和研究热点。Polo样蛋白激酶1(Polo-like kinase 1,Plk1)是一种广泛存在于真核生物中的丝氨酸/苏氨酸蛋白激酶,在人类多数肿瘤中表达水平较高,近年来被认为是治疗恶性肿瘤的干预靶点,靶向Plk1的乳腺癌治疗已成为近年来关注的热点。本文对Plk1与乳腺癌发生、发展及转移的相关性,以及目前靶向Plk1的乳腺癌治疗策略进行综述。

Breast cancer is one of the most common malignant tumors in women.With a high incidence,breast cancer is prone to recurrence and metastasis,which shows a tendency of occurrence in younger population.Targeted therapy is the research hotspot of breast cancer treatment.Polo-like kinase 1(Plk1)is a serine/threonine protein kinase which exists widely in eukaryotes and is highly expressed in most of human tumors.At present,Plk1 is a promising intervention target for the treatment of malignant tumors.The therapy targeting Plk1 of breast cancer has become a hotspot in recent years.This article reviews the relationship of Plk1 to the pathopoiesis,progress and metastasis of breast cancer as well as the current strategy targeting Plk1 for treatment of breast cancer.